In this study, we systematically re-assessed HER2 copy number, HER2/CEP17 ratio and ERBB2 mRNA in a trastuzumab-treated breast cancer cohort and investigated the biomarkers in a continuous manner in relation to RFS. Here, ERBB2 is linked to breast carcinoma.